1. Home
  2. YEXT vs MNPR Comparison

YEXT vs MNPR Comparison

Compare YEXT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yext Inc.

YEXT

Yext Inc.

HOLD

Current Price

$6.47

Market Cap

648.3M

Sector

Technology

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$85.24

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YEXT
MNPR
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
648.3M
587.4M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
YEXT
MNPR
Price
$6.47
$85.24
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
$7.50
★ $107.00
AVG Volume (30 Days)
★ 1.0M
102.0K
Earning Date
06-02-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 131.82
54.99
EPS
★ 0.15
N/A
Revenue
★ $170,201,000.00
N/A
Revenue This Year
$3.95
N/A
Revenue Next Year
$2.46
N/A
P/E Ratio
$43.27
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.27
$50.07
52 Week High
$9.03
$124.82

Technical Indicators

Market Signals
Indicator
YEXT
MNPR
Relative Strength Index (RSI) 56.39 25.28
Support Level $6.04 $52.12
Resistance Level $7.99 $123.37
Average True Range (ATR) 0.24 4.81
MACD -0.03 -2.53
Stochastic Oscillator 71.13 3.00

Price Performance

Historical Comparison
YEXT
MNPR

About YEXT Yext Inc.

Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: